Cargando…

Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer

PURPOSE: To determine the impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcome. The main purpose and research question of the study is to determine the impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes. METHODS: Prospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Porcu, Eleonora, Cillo, Giulia Maria, Cipriani, Linda, Sacilotto, Federica, Notarangelo, Leonardo, Damiano, Giuseppe, Dirodi, Maria, Roncarati, Ilaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125060/
https://www.ncbi.nlm.nih.gov/pubmed/31872386
http://dx.doi.org/10.1007/s10815-019-01658-9
_version_ 1783515867126956032
author Porcu, Eleonora
Cillo, Giulia Maria
Cipriani, Linda
Sacilotto, Federica
Notarangelo, Leonardo
Damiano, Giuseppe
Dirodi, Maria
Roncarati, Ilaria
author_facet Porcu, Eleonora
Cillo, Giulia Maria
Cipriani, Linda
Sacilotto, Federica
Notarangelo, Leonardo
Damiano, Giuseppe
Dirodi, Maria
Roncarati, Ilaria
author_sort Porcu, Eleonora
collection PubMed
description PURPOSE: To determine the impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcome. The main purpose and research question of the study is to determine the impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes. METHODS: Prospective study: 67 breast cancer patients between 18 and 40 years old, undergoing a fertility preservation by means of oocyte storage were considered. Inclusions criteria for the study were age between 18 and 40 years old, BMI between 18 and 28, breast cancer neoplasm stage I and II according to American Joint Committee on Cancer classification (2017) and no metastasis. Exclusion criteria: age over 40 years old, BMI < 18 and > 28, breast cancer neoplasm stage III and IV and do not performed the BRCA test. A total of 21 patients had not performed the test and were excluded. Patients were divided into four groups: Group A was composed by 11 breast cancer patients with BRCA 1 mutations, Group B was composed by 11 breast cancer patients with BRCA 2 mutations, Group C was composed by 24 women with breast cancer without BRCA mutations, and Group D (control) was composed by 181 normal women. RESULTS: Group A showed significant lower AMH levels compared to Group C and D (1.2 ± 1.1 vs 4.5 ± 4.1 p < 0.05 and 1.2 ± 1.1 vs 3.8 ± 2.5 p < 0.05). BRCA1 mutated patients showed a significant lower rate of mature oocytes (MII) compared to Group C (3.1 ± 2.3 vs 7.2 ± 4.4 p < 0,05) and Group D (3.1 ± 2.3 vs 7.3 ± 3.4; p < 0,05). Breast cancer patients needed a higher dose of gonadotropins compared to controls (Group A 2206 ± 1392 Group B2047.5 ± 829.9 Group C 2106 ± 1336 Group D 1597 ± 709 p < 0,05). No significant differences were found among the groups considering basal FSH levels, duration of stimulation, number of developed follicles, and number of total retrieved oocytes. Regarding BRCA2 mutation, no effect on fertility was shown in this study. CONCLUSIONS: The study showed that BRCA1 patients had a higher risk of premature ovarian insufficiency (POI) confirmed by a diminished ovarian reserve and a lower number of mature oocytes suitable for cryopreservation.
format Online
Article
Text
id pubmed-7125060
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-71250602020-04-06 Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer Porcu, Eleonora Cillo, Giulia Maria Cipriani, Linda Sacilotto, Federica Notarangelo, Leonardo Damiano, Giuseppe Dirodi, Maria Roncarati, Ilaria J Assist Reprod Genet Fertility Preservation PURPOSE: To determine the impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcome. The main purpose and research question of the study is to determine the impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes. METHODS: Prospective study: 67 breast cancer patients between 18 and 40 years old, undergoing a fertility preservation by means of oocyte storage were considered. Inclusions criteria for the study were age between 18 and 40 years old, BMI between 18 and 28, breast cancer neoplasm stage I and II according to American Joint Committee on Cancer classification (2017) and no metastasis. Exclusion criteria: age over 40 years old, BMI < 18 and > 28, breast cancer neoplasm stage III and IV and do not performed the BRCA test. A total of 21 patients had not performed the test and were excluded. Patients were divided into four groups: Group A was composed by 11 breast cancer patients with BRCA 1 mutations, Group B was composed by 11 breast cancer patients with BRCA 2 mutations, Group C was composed by 24 women with breast cancer without BRCA mutations, and Group D (control) was composed by 181 normal women. RESULTS: Group A showed significant lower AMH levels compared to Group C and D (1.2 ± 1.1 vs 4.5 ± 4.1 p < 0.05 and 1.2 ± 1.1 vs 3.8 ± 2.5 p < 0.05). BRCA1 mutated patients showed a significant lower rate of mature oocytes (MII) compared to Group C (3.1 ± 2.3 vs 7.2 ± 4.4 p < 0,05) and Group D (3.1 ± 2.3 vs 7.3 ± 3.4; p < 0,05). Breast cancer patients needed a higher dose of gonadotropins compared to controls (Group A 2206 ± 1392 Group B2047.5 ± 829.9 Group C 2106 ± 1336 Group D 1597 ± 709 p < 0,05). No significant differences were found among the groups considering basal FSH levels, duration of stimulation, number of developed follicles, and number of total retrieved oocytes. Regarding BRCA2 mutation, no effect on fertility was shown in this study. CONCLUSIONS: The study showed that BRCA1 patients had a higher risk of premature ovarian insufficiency (POI) confirmed by a diminished ovarian reserve and a lower number of mature oocytes suitable for cryopreservation. Springer US 2019-12-24 2020-03 /pmc/articles/PMC7125060/ /pubmed/31872386 http://dx.doi.org/10.1007/s10815-019-01658-9 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Fertility Preservation
Porcu, Eleonora
Cillo, Giulia Maria
Cipriani, Linda
Sacilotto, Federica
Notarangelo, Leonardo
Damiano, Giuseppe
Dirodi, Maria
Roncarati, Ilaria
Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer
title Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer
title_full Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer
title_fullStr Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer
title_full_unstemmed Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer
title_short Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer
title_sort impact of brca1 and brca2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer
topic Fertility Preservation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125060/
https://www.ncbi.nlm.nih.gov/pubmed/31872386
http://dx.doi.org/10.1007/s10815-019-01658-9
work_keys_str_mv AT porcueleonora impactofbrca1andbrca2mutationsonovarianreserveandfertilitypreservationoutcomesinyoungwomenwithbreastcancer
AT cillogiuliamaria impactofbrca1andbrca2mutationsonovarianreserveandfertilitypreservationoutcomesinyoungwomenwithbreastcancer
AT ciprianilinda impactofbrca1andbrca2mutationsonovarianreserveandfertilitypreservationoutcomesinyoungwomenwithbreastcancer
AT sacilottofederica impactofbrca1andbrca2mutationsonovarianreserveandfertilitypreservationoutcomesinyoungwomenwithbreastcancer
AT notarangeloleonardo impactofbrca1andbrca2mutationsonovarianreserveandfertilitypreservationoutcomesinyoungwomenwithbreastcancer
AT damianogiuseppe impactofbrca1andbrca2mutationsonovarianreserveandfertilitypreservationoutcomesinyoungwomenwithbreastcancer
AT dirodimaria impactofbrca1andbrca2mutationsonovarianreserveandfertilitypreservationoutcomesinyoungwomenwithbreastcancer
AT roncaratiilaria impactofbrca1andbrca2mutationsonovarianreserveandfertilitypreservationoutcomesinyoungwomenwithbreastcancer